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Abstract
Polymorphisms within one-carbon metabolism genes have been largely studied in relation
to cancer risk for the function of this pathway in nucleotide synthesis and DNA methylation.
Aims of this study were to explore the possible link among several common functional gene
polymorphisms within one-carbon metabolism and survival rate in primary liver cancers, i.e.,
hepatocellular carcinoma and cholangiocarcinoma, and to assess the additional effect of
global DNA methylation on survival rate and mortality risk. Forty-seven primary liver cancer
patients were genotyped for ten polymorphisms: DHFR 19bp ins/del, TS 2rpt-3rpt, MTHFD1
1958G>A, MTHFR 677C>T, MTR 2756A>G, MTRR 66A>G, RFC1 80G>A, SHMT1
1420C>T, BHMT 716 A>G, TC II 776C>G. Methylation was determined in peripheral blood
mononuclear cells (PBMCs) DNA as methylcytosine (mCyt) content using LC/MS/MS.
Among the polymorphisms analysed, the RFC1 80G>A (rs1051266) influenced the survival
rate in primary liver cancers. The RFC1 80AA was associated to a significantly reduced sur-
vival rate (22.2%) as compared to both GG and GA genotypes (61.5% and 76% respec-
tively, p = 0.005). When the cancer patients were stratified according to the mCyt median
value as high (>5.34%) or low (5.34%), the concomitant presence of AA genotype and low
mCyt level led to a significantly worse survival rate as compared to the G allele carriership
(p<0.0001) with a higher Hazard Ratio (HR = 6.62, p = 0.001). The subjects carrying the AA
genotype in association with high mCyt did not show a significant difference in survival rate
as compared with the G allele carriers (p = 0.919). The RFC1 80G>A polymorphism influ-
enced the survival rate, and the presence of RFC1 80AA genotype with low global methyla-
tion in PBMCs DNA was associated with poorer prognosis and higher mortality risk,
therefore highlighting novel molecular signatures potentially helpful to define prognostic
markers for primary liver cancers.
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Introduction
One-carbon metabolism is essential for several intracellular reactions including those involved
in nucleotide synthesis and biological methylation, in particular methylation of DNA, the
major epigenetic mechanism in mammalian cells [1].
Genetic variants of one-carbon pathway genes have been investigated mainly in colon can-
cer as potential markers of cancer susceptibility [2–5] for the involvement of this metabolism
in cellular development, proliferation and differentiation [6, 7]. The molecular mechanisms
underlying the possible association among polymorphic variants of one-carbon metabolism
genes, cancer survival rate and mortality risk are, however, not completely clarified.
DNA methylation is a heritable and reversible phenomenon that consists in the covalent
binding of a methyl group to the 5’carbon of a cytosine in CpG dinucleotide sequences and it
plays a role in gene expression regulation and maintenance of genomic stability [8–10]. An
aberrant DNAmethylation, both global and gene-specific, is involved throughout all the
phases of cancer development and progression, and a status of global DNA hypomethylation is
an almost universal finding in cancer tissues [11, 12]. A global hypomethylation in peripheral
blood mononuclear cells (PBMCs) DNA was associated to an increased cancer risk [13] and a
shorter survival rate in patients affected by different types of cancer [14–16]. In recent studies,
we observed significantly reduced methylcytosine (mCyt) levels in PBMCs DNA of cancer
patients [17, 18] and lower levels were directly associated to an unfavourable prognosis [18].
As for the possible relationship among one-carbon metabolism gene variants, global DNA
methylation and cancer, we previously reported that the TT genotype of theMTHFR 677C>T
polymorphism associated with low plasma folate levels presented a decreased DNAmethyla-
tion [19] and higher incidence of cancer [17]. Global DNA hypomethylation in PBMCs in
association with the carriership ofMTHFR T allele represents, therefore, a predicting factor of
cancer development and an unfavourable prognostic factor in cancer disease [17]. The poten-
tial association among other polymorphic variants of one-carbon metabolism genes, global
DNAmethylation in PBMCs and survival rate in cancer is still poorly investigated as it is the
role of aberrant DNAmethylation in clinical outcome and prognosis in cancer disease.
Cancer is a major public health issue [20] and among the different cancer types, primary
liver cancers, i.e. hepatocellular carcinoma and cholangiocarcinoma, are prevailing malignan-
cies with a high worldwide mortality rate [21].
Aims of the present study were: i) to explore the possible link among the most common var-
iants of one carbon-related genes and survival rate in primary liver cancers, i.e. hepatocellular
carcinoma and cholangiocarcinoma, and ii) to assess the additional effect of global DNAmeth-
ylation on survival rate and mortality risk.
Materials and Methods
Study subjects and survival data collection
The study was approved by the Institutional Review Board Ethical Committee of the Univer-
sity of Verona School of Medicine Hospital (Verona, Italy). Written informed consent was
obtained from each patient after a detailed explanation of the study.
Forty-seven patients affected by primary liver cancers, 31 hepatocellular carcinoma and 16
cholangiocarcinoma, were enrolled from April 2009 to March 2013 among those referring to
the Division of Surgery of the Verona University Hospital for curative surgery intervention.
Inclusion criteria were age 18 years with the following surgical resectability criteria: preserved
liver function, class A Child-Pugh score, absence of extrahepatic metastases. Exclusion criteria
were a coexisting human immunodeficiency (HIV), hepatitis B (HBV) or hepatitis C (HCV)
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viruses infection; presence of relevant concurrent medical conditions such as chronic inflam-
matory diseases or haematological disorders, including autoimmune liver diseases and heredi-
tary hemochromatosis; presence of an acute inflammatory disease, decompensate liver cirrhosis
(Child-Pugh B, C). A trained physician recorded a detailed clinical history data including life-
style habits. All subjects under B vitamins supplementation and/or using drugs known to inter-
fere with folate-related one-carbon metabolism in the month before enrolment were excluded.
A periodic evaluation of the patients consisting in a complete medical examination or a
telephone interview was performed during a follow-up period of 60 months. The follow-up
period was calculated from the date of the surgical intervention up to the date of death or to
the latest recorded medical examination.
Biochemical analyses
Samples of venous blood were drawn from each subject after an overnight fasting and analysed
by routine laboratory test analysis for a complete blood count and determination of serum C-
reactive protein (CRP), creatinine, aspartate transaminase (AST), alanine transaminase (ALT),
gamma-glutamyltranspeptidase (gGT), alkaline phosphatase (ALP), total bilirubin, albumin,
glycemic level, total cholesterol, triglycerides, prothrombin time-international ratio (PT-INR),
ferritin, serological tests for hepatitis B and C viruses. Plasma folate and vitamin B12 were
measured by an automated chemiluminescence method (ChironDiagnostics, East Walpole,
MA, USA) and total plasma homocysteine concentrations was determined by high-perfor-
mance liquid chromatography (HPLC) with fluorescent detection [22].
Genotyping
From each subject venous blood was drawn into Vacutainer1 tubes containing EDTA as antico-
agulant after an overnight fast and DNA was extracted from PBMCs byWizard Genomic DNA
Purification Kit (Promega Corporation, Fitchburg, WI, USA). One carbon metabolism gene
variants were analysed by different methods, as follows: DHFR 19bp ins/del [23] and TS 2rpt-
3rpt [24] by PCR;MTHFD1 1958G>A (rs2236225) [25],MTHFR 677C>T (rs1801133) [26],
MTR 2756A>G (rs12749581) [27],MTRR 66A>G (rs1801394) [28], RFC1 80G>A (rs1051266)
[29] and SHMT1 1420C>T (rs1979277) [30] by PCR followed by restriction fragment length
polymorphism assays, BHMT 716 A>G (rs3733890) and TC II 776C>G (rs1801198) by allelic
discrimination Real Time-PCR technology using the assay C_11646606_20 and the assay
C_325467_10, respectively (ABI Prism 7500, Applied Biosystems, Carlsbad, CA, USA).
Global DNA methylation
Global DNAmethylation was determined using a liquid chromatography/mass spectrometry
(LC/MS/MS) method and mCyt levels expressed as percent (%)mCyt = [(mCyt)/(mCyt +
Cyt)] x 100, as previously described [19, 31], with slight modifications [18]. Briefly, global
DNA was extracted from PBMCs and hydrolyzed to nucleosides using 2 units of nuclease P1,
0.002 units of venom phosphodiesterase I and 0.5 units of alkaline phosphatase. Isotope-
labelled internal standards for deoxycytidine and 5-methyl-deoxycytidine were added to sam-
ples before the run in a 3200 Q Trap MS-MS system coupled with an Agilent 1100 Series liquid
chromatograph (Agilent, Santa Clara, CA, USA).
Statistical analysis
All the statistical computations were performed by using the IBM SPSS Statistics software ver-
sion 22 for Windows (IBM Inc., Armonk, NY, USA). Continuous variables were expressed as
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mean values ± standard deviations (SD), parameters showing a skewed distribution were log-
transformed and thus expressed as geometric means with 95% confidence intervals (CIs).
Continuous variables were tested by analysis of variance (ANOVA) with Tukey’s post-hoc
comparison when appropriate. All genotype distributions were verified to be in agreement
with Hardy-Weinberg equilibrium.
Survival rate was analysed by Kaplan-Meier curves with Log Rank test and pairwise com-
parison when indicated. Hazard ratio (HR) of mortality with 95% CI was estimated by Cox
regression analysis adjusted for age and gender, and by including folate plasma concentration
in the regression model. A p-value<0.05 was considered statistically significant.
Results
Clinical and biochemical characteristics of primary liver cancer patients
Table 1 reports the main clinical and biochemical characteristics of the 47 primary liver cancer
patients (31 hepatocellularcarcinoma, 16 cholangiocarcinoma). The main biochemical analy-
ses were within the normal range and, in particular, the indexes of hepatic function confirmed
a compensated liver function status in all patients (Table 1). Viral serologic tests for HBV
and HCV were negative in all patients according to the enrolment criteria. As for neoplastic
markers, alpha-fetoprotein values were within the normal range (<7 g/l) in 39% of the HCC
patients, whereas normal levels of CA 19.9 (<25 U/ml) and CEA (<5 ng/ml) were observed in
50% and 100% of CC patients, respectively.
Survival rate according to one-carbon polymorphic variants
The polymorphic variants distribution of all evaluated one-carbon metabolism genes was in
agreement with the Hardy-Weinberg equilibrium in the study subjects.
The Kaplan-Meier analysis to test the survival rate was performed in accordance to the ten
gene polymorphic variants object of the study. Among the analysed polymorphisms, only the
RFC1 80G>A polymorphism influenced the survival rate in primary liver cancers. The RFC1
80G>A genotypes frequencies are reported in Table 2. The homozygous variant RFC1 80AA
was associated to a lower survival rate (22.2%) as compared to both RFC1 80 GG and GA geno-
types (survival rate 61.5% and 76% respectively, p = 0.005) (Fig 1A). The statistical significance
increased when the RFC1 80AA subjects were compared to the G allele carriers (RFC1 80 GG +
GA) (Fig 1B) with a survival rate of 22.2% versus 71.1%, respectively (p = 0.002). When the
main biochemical parameters, in particular plasma folate levels, were analysed according to
the RFC1 80G>A variants, no significant differences were observed among the three genotypes
except for platelet count, higher in the AA group, and triglycerides concentration that was
lower in the GG genotype group (data not shown).
RFC1 80G>A genotypes and survival rate according to DNA global
methylation
The observed association of RFC1 80G>A polymorphism with survival rate in primary liver
cancer (Fig 1) suggested to evaluate mCyt levels according to RFC1 80G>A genotypes. The
comparison of mCyt levels showed no statistically significant differences among the genotypes
(AA 5.41%, GA 5.36% and GG 5.25%, p = 0.607). The methylation status did not differ also
when comparing 80AA subjects with G allele carriers (RFC1 80GG + GA) (5.41% versus 5.32%,
respectively, p = 0.553) (data not shown).
Subsequently the study group was stratified in two subsets according to high (>5.34%) or
low (5.34%) global DNAmethylation, defined on mCyt median value, and the survival rate
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evaluated by Kaplan—Meier analysis. RFC1 80AA patients with low mCyt had a significantly
worse survival in comparison both with GA and GG subjects, either with low or high mCyt
levels (p = 0.002) (data not shown). Since the RFC1 80G carriers exhibited similar survival rate
curves, the two groups were merged and the Kaplan—Meier analysis repeated. The plotted
Table 1. Clinical and biochemical characteristics of primary liver cancer patients.
References values Cancer patients (n = 47)
Clinical characteristics
Age, years 67.1 ± 9.0
Gender, % male 76.6%
Smoking 68.1%
Alcohol drinking 72.3%
Laboratory tests
CRP (mg/L)* <5 7.70 (5.13–11.55)
Hb (g/dL) 13.5–16.0 13.5 ± 1.62
MCV (fL) 86–98 91.9 ± 7.49
WBCs (109/L) 4.3–10.0 7.01 ± 2.96
PLTs (109/L) 150–400 235.6 ± 119.9
AST (U/L)* 8–50 41.7 (32.8–53.2)
ALT (U/L)* 8–45 40.8 (30.2–55.0)
ALP (U/L)* 30–130 92.4 (77.9–109.6)
gGT (U/L)* <50 76.7 (58.6–100.3)
Total bilirubin (mg/dL)* 0.11–1.05 0.71 (0.59–0.86)
Direct bilirubin (mg/dL)* <0.35 0.25 (0.20–0.31)
PT (INR)* 0.82–1.14 1.11 (1.07–1.15)
Albumin (g/L) 35–50 39.9 ± 5.54
CHE (U/L) 4650–14400 6515 ± 1890
Total cholesterol (mg/dL) <200 159.5 ± 48.9
Triglycerides (mg/dL)* <150 112.7 (100.1–126.7)
Creatinine (mg/dL)* 0.59–1.29 0.86 (0.74–1.00)
Glucose (mmol/L) 3.5–5.5 6.39 ± 1.81
Folate (nmol/L)* 10.4–42.4 8.52 (9.95–10.45)
tHcy (μg/L)* < 15 13.2 (10.4–16.7)
Vitamin B12 (pmol/L)* 142–724 337.0 (288.4–393.8)
Vitamin B6 (nmol/L)* 25–128 19.7 (15.4–25.2)
Ferritin (μg/L)* 30–400 249.4 (178.2–349.0)
Values are expressed as mean ± SD.
*: log-transformed variables are shown as geometric mean with 95% confidence interval
Alcohol drinking defined as  36 g ethanol/day for males and  24 g ethanol/day for females
Abbreviations: CRP, C-reactive protein; Hb, Hemoglobin; MCV, Mean Corpuscular Volume; WBCs, White Blood Cells; PLTs, Platelets; AST, aspartate
aminotransferase; ALT, aspartate alanine aminotransferase; ALP, Alkaline phosphatase; gGT, gamma glutamyl transferase; PT (INR), Prothrombin
International Ratio; CHE, cholinesterase; tHcy, Homocysteine.
doi:10.1371/journal.pone.0167534.t001
Table 2. RFC1 80G>A genotypes frequencies in primary liver cancer patients (n = 47).
RFC1 80GG RFC1 80GA RFC1 80AA
Number of patients 13 25 9
Percentage of patients 27.7% 53.2% 19.1%
doi:10.1371/journal.pone.0167534.t002
RFC1 80G>A and Survival Rate According to DNA Methylation in Primary Liver Cancers
PLOS ONE | DOI:10.1371/journal.pone.0167534 December 9, 2016 5 / 13
curves highlighted that RFC1 80AA patients with low mCyt levels had a poorer survival rate, as
compared with G allele carriers (p<0.0001) (Fig 2). Noteworthy, all the five patients character-
ized by RFC1 80AAwith low mCyt were deceased at the time of observation, whereas both the
RFC1 80G carriers and RFC1 80AAwith high mCyt showed better survival rates (71.1% and
50%, respectively). No statistically significant differences were found when comparing the
RFC1 80G carriers and the RFC1 80AAwith high mCyt (p = 0.919) and when comparing RFC1
80AAwith low mCyt and RFC180AAwith high mCyt (p = 0.209) (Fig 2).
RFC1 80G>A genotypes and mortality risk according to global DNA
methylation
The analysis of mortality risk was performed by setting the RFC1 80G carriership as the refer-
ence group with Hazard Ratio (HR) = 1 and the mortality risk associated to RFC1 80AA geno-
type with high or low mCyt levels was calculated. Subjects carrying the RFC1 80AA genotype
and high mCyt had an HR = 2.05, not statistically different from the reference group, whereas
the concomitant presence of RFC1 80AA genotype and low mCyt was associated to a 6.62-fold
higher HR, as compared to RFC1 80G carriers (p = 0.001) (Fig 3).
The HR significantly increased when the analysis was performed after adjustments for age
and gender (HR = 8.35 CI 2.42–28.67, p = 0.001) and for age, gender and plasma folate con-
centrations (HR = 9.78 CI 2.34–40.94, p = 0.002) (Fig 4).
Discussion
The results of this study indicates that primary liver cancer patients carrying the RFC1 80AA
genotype associated with low DNAmethylation have a significantly poorer survival rate with a
higher mortality risk, as compared with G allele carriers.
Fig 1. Survival curves plotted by Kaplan-Meier analysis according to RFC1 80G>A genotypes. (A) The survival rate was
worse in RFC1 80AA (22.2%) patients as compared to the RFC1 80GA (76%) and RFC1 80GG (61.5%) genotypes (p = 0.005). (B)
The survival rate was lower among the RFC1 80 AA patients as compared with the G allele carriers (RFC1 80GG+GA) (p = 0.002).
The percentage of survivors was 22.2% and 71.1%, respectively.
doi:10.1371/journal.pone.0167534.g001
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The Reduced Folate Carrier 1 (RFC1, official symbol SLC19A1) gene is located on chromo-
some 21 and encodes for an ubiquitously expressed transmembrane protein that serves as a bi-
directional transporter of reduced folate species such as 5-methyl THF, the main circulating
active form of folate [32, 33] and it is involved in both methylation pathway and nucleotides
synthesis.
Chango et al., described a RFC1 polymorphic variant (rs 1051266) consisting in the substi-
tution of a guanine to an adenine (G>A) at position 80 of gene sequence, causing an arginine
to histidine substitution at amino acid position 27 [29]. The exact functional relevance of this
variant is, however, still unclear [34, 35]. In several human and animal studies no significant
differences were observed both in plasma and red blood cell folate concentration in association
with RFC1 80G>A genotypes [29, 36–42]. Results from the present study confirmed the lack of
Fig 2. Survival curves plotted by Kaplan-Meier analysis according to RFC1 80G>A genotypes and mCyt
levels. RFC1 80AA patients with low mCyt levels (5.34%) were associated to a lower survival as compared to
carriers of the RFC1 80G allele (71.1%) (p<0.0001). The comparison between RFC1 80G carriers and RFC1 80AA
with high mCyt (>5.34%) was not statistically significant (p = 0.919), as it was the comparison between RFC1 80AA
with low mCyt and with high mCyt (p = 0.209).
doi:10.1371/journal.pone.0167534.g002
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differences in plasma folate concentrations according to the RFC1 80G>A genotypes. The
RFC1 80G>A polymorphism might be associated to a lower availability of methyl groups at tis-
sue level for methylation reaction rather than to an evidently reduced level of plasma folate.
The relationship among the RFC1 80G>A polymorphism, cancer risk and clinical outcome
have been the objects of several studies, though with contrasting reports.
RFC1 80G allele was associated with an increased risk of head and neck carcinoma [43, 44],
whereas an increased risk of gastric and esophageal cancer was found in association with the
RFC180AA genotype [45]. The RFC1 80AA genotype was also associated with increased risk
for acute lymphoid leukaemia with worse outcome [46], higher chance of relapse and poorer
survival [47, 48] as compared to GA and GG genotypes. On the contrary, in patients affected
by rectal cancer the RFC1 80AA genotype was associated with a more favourable prognosis
[49]. On the other hand, no association was found between RFC1 80G>A genotypes and breast
cancer risk [50] or survival [51].
Global DNA hypomethylation is associated with genomic instability and compromised
gene repression in genomic regions that are usually silenced in normal cells [11, 12, 52]. The
consequence of this event may entail the expression of proto-oncogenes as well as the activa-
tion of viral and parasitic transposons [52, 53]. Moreover, it has been consistently demon-
strated that DNA hypomethylation is able to increase the immunogenicity and the immune
recognition of cancer cells, thus affecting transcriptional deregulation and tumour aggres-
siveness [52]. Most of the studies showing an aberrant DNA methylation evaluated this epige-
netic feature of DNA at the level of the specific tissue affected by the malignant process. One
Fig 3. Mortality risk by Hazard Ratio for RFC1 80AA genotype with either high or low mCyt levels. The
RFC1 80AA genotype with low mCyt levels (5.34%), had a higher Hazard Ratio (HR) as compared to RFC1
80G carriership (RFC1 80GA plus RFC1 80GG) (HR = 6.62, 95% CI 2.17–20.25, p = 0.001). The HR for RFC1
80AA genotype with high mCyt levels (>5.34%) did not differ from the RFC1 80G carriership group (HR = 2.05,
95% CI 0.45–9.32, p = 0.351).
doi:10.1371/journal.pone.0167534.g003
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key point for discussion is, in fact, the finding of low methylation levels measured in PBMCs
DNA. Considering that epigenetic mechanisms including methylation are usually considered
tissue-specific, some speculations in this regard are needed. It has been suggested that a global
DNA hypomethylation status in PBMCs might represent a potential epigenetic marker for
cancer [13] and low levels of mCyt are usually associated to increased cancer risk and to poor
prognosis [13–16]. In a previous study we demonstrated that patients affected by different
types of cancer had a significantly lower global methylation in PBMCs DNA as compared to
cancer-free controls and that DNA hypomethylation was also associated with a higher risk for
cancer development [17]. Moreover, in a recent study in primary liver cancer patients we dem-
onstrated that low mCyt levels in PBMCs DNA were related to a worse prognosis, suggesting a
putative prognostic relevance of DNAmethylation [18]. A recent prospective case-control
study reported that RFC1 80G>A is associated with LINE-1 undermethylation as measured in
peripheral blood DNA of women who developed breast cancer as compared with breast can-
cer-free controls [54]. Nevertheless, whilst the RFC1 80G>A variant was associated to lower
methylation, no relationship was found between the presence of the variant and cancer risk
[54].
The results of the present study demonstrate that the RFC1 80AA genotype is significantly
associated with a poorer life expectancy in primary liver cancer patients. Moreover, when the
mCyt levels were stratified as either high (>5.34%) or low (5.34%), patients with the RFC1
80AA genotype and low mCyt showed a significantly worse survival rate and a higher mortality
risk as compared to the RFC1 80G carriers, even after adjustments for sex, age and folate con-
centrations. Noteworthy, the five patients characterized by the RFC1 80AA genotype and low
mCyt levels were all deceased at the time of the observation.
Fig 4. Mortality risk associated to carriership of the RFC1 80AA genotype with low mCyt using crude
Hazard Ratio and after adjustments for age, gender and folate. The unadjusted Hazard Ratio (HR) was
6.62 (95% CI 2.17–20.25, p = 0.001) and the value significantly increased after adjustments for age and
gender (HR = 8.35, 95% CI 2.42–28.67, p = 0.001) and for age, gender and plasma folate concentrations
(HR = 9.78, 95% CI 2.34–40.94, p = 0.002).
doi:10.1371/journal.pone.0167534.g004
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The mechanism by which global DNA hypomethylation in the presence of the RFC1 80AA
genotype may entail a poorer prognosis in patients affected by primary liver cancer remains to
be explored. RFC1 is a key transmembrane bi-directional transporter of 5-methyl THF, the
main circulating active form of folate, and it is involved in both methylation pathway and
nucleotides synthesis. The present results showed that the AA genotype is associated to lower
survival in primary liver cancer and that the AA genotype and concomitant low mCyt levels
have a significantly poorer survival rate with a higher mortality risk. One hypothesis for the
explanation of this finding is that RFC1 might be involved in carcinogenesis by affecting both
methylation reactions and DNA repair capacity.
Even if the results of this study suggest that primary liver cancer patients showing RFC1
80AA genotype and low global DNAmethylation at the enrolment, are at risk for poorer sur-
vival, further validation is required to assess whether this genetic-epigenetic fingerprint may
be used as a clinically valuable prognostic tool. The reliable identification of prognostic molec-
ular biomarkers may assume an important role in the clinical decision process for tailored
therapeutic approaches in cancer treatment and in the improvement of cancer prognosis. Fur-
ther investigations are certainly warranted to clarify the biological effect of RFC1 80G>A and
the prognostic significance of PBMCs global DNAmethylation assessment in primary liver
cancers.
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